Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Stereotactic body radiation therapy (SBRT) followed by sorafenib in HCC improves OS

ASCO GI 2023

19 - 21 Jan 2023

Published: 7 Feb 2023

Views: 74

Rating:

Save

Prof Laura Dawson - University of Toronto, Toronto, Canada

Prof Laura Dawson speaks to ecancer about her randomised phase III study of sorafenib vs. SBRT followed by sorafenib in hepatocellular carcinoma.

The study investigated if SBRT followed by sorafenib (SBRT/S) improves overall survival (OS), progression-free survival (PFS) and quality of life (QOL) vs. sorafenib alone (S), in patients with HCC.

Compared to sorafenib alone, SBRT improved OS & PFS in patients with HCC, with no observed increase in adverse events, and a strong suggestion for QOL benefit at 6 months. Prof Dawson concludes by talking about the clinical impact of these results.

Related Videos

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new...

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France

Isatuximab plus lenalidomide and dexamethasone with bortezomib as a new standard of care for NDMM TI non-frail patients ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM

Dr Elias Mai - Heidelberg University, Heidelberg, Germany

Made to measure: Choosing the optimal regimen in transplant-eligible NDMM ( Dr Elias Mai - Heidelberg University, Heidelberg, Germany )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Guiding transplant decisions in multiple myeloma with MRD

Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA

Guiding transplant decisions in multiple myeloma with MRD ( Dr Susan Bal - University of Alabama at Birmingham, Birmingham, USA )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced...

Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours ( Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA )

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy...

Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China

New NK-1 inhibitor HR20013 shows promising results in preventing chemotherapy-induced nausea and vomiting in NSCLC patients ( Dr Li Zhang - Sun Yat-Sen University Cancer Centre, Guangzhou, China )

Advancements in paediatric Acute lymphoblastic leukemia management

Dr Ruchi Aujla - Balco Medical Center, Raipur, India

Advancements in paediatric Acute lymphoblastic leukemia management ( Dr Ruchi Aujla - Balco Medical Center, Raipur, India )

Enhancing head and neck oncology: Key insights from the conference

Dr Anil D'Cruz - Apollo Hospitals, Mumbai, India

Enhancing head and neck oncology: Key insights from the conference ( Dr Anil D'Cruz - Apollo Hospitals, Mumbai, India )

More from ecancer